Real-world efficacy and safety of dupilumab in children with
atopic dermatitis under 6 years of age: a retrospective
multicentric study

J 2025

Real-world efficacy and safety of dupilumab in children with atopic dermatitis under 6 years of age: a retrospective multicentric study

ROB, Filip; Blanka PINKOVÁ; Kristyna SOKOLOVA; Jana KOPULETA; Zuzana JIRASKOVA ZAKOSTELSKA et al.

Základní údaje

Originální název

Real-world efficacy and safety of dupilumab in children with atopic dermatitis under 6 years of age: a retrospective multicentric study

Autoři

ROB, Filip; Blanka PINKOVÁ; Kristyna SOKOLOVA; Jana KOPULETA; Zuzana JIRASKOVA ZAKOSTELSKA a Jana CADOVA

Vydání

Journal of Dermatological Treatment, ABINGDON, TAYLOR & FRANCIS LTD, 2025, 0954-6634

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30216 Dermatology and venereal diseases

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 3.900 v roce 2024

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/25:00141882

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

Atopic dermatitis; dupilumab; biologics; children; efficacy; safety

Štítky

14110317, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 1. 9. 2025 09:36, Mgr. Tereza Miškechová

Anotace

V originále

In this multicentric real-world observational retrospective study, we evaluated the efficacy and safety of dupilumab for atopic dermatitis in children <6 years of age who underwent a minimum of 16 weeks of therapy. The analysis focused on EASI (Eczema Area and Severity Index), CDLQI (Children's Dermatology Life Quality Index), and Itch NRS (Numeric Rating Scale) changes from baseline to 4, 16, 24, 48, 72, and 96 weeks of follow-up (when available). Overall 24 children were included, with a mean age of 4.4 years. The baseline mean EASI among these patients was 26.7 (range 11.2-42.5). Since week 16 of therapy, all patients achieved and sustained at least 50% (EASI-50) atopic dermatitis improvement from baseline for the remainder of the follow-up period. At week 16, the mean EASI was 4.6 (0.8-13.1), EASI-75 reached 75% and EASI-90 38% of the patients. Within the initial 16 weeks of dupilumab treatment, 50% of patients experienced at least one adverse event, none of which were deemed severe. Conjunctivitis was among the most common adverse events (8.3%). In conclusion, dupilumab exhibited favorable tolerability, efficacy, and safety in children diagnosed with atopic dermatitis who were below the age of 6.

Citovat

ROB, Filip; Blanka PINKOVÁ; Kristyna SOKOLOVA; Jana KOPULETA; Zuzana JIRASKOVA ZAKOSTELSKA a Jana CADOVA. Real-world efficacy and safety of dupilumab in children with atopic dermatitis under 6 years of age: a retrospective multicentric study. Journal of Dermatological Treatment. ABINGDON: TAYLOR & FRANCIS LTD, 2025, roč. 36, č. 1, s. 1-4. ISSN 0954-6634. Dostupné z: https://doi.org/10.1080/09546634.2025.2460578.

@article{2514906,
   author = {Rob, Filip and Pinková, Blanka and Sokolova, Kristyna and Kopuleta, Jana and Jiraskova Zakostelska, Zuzana and Cadova, Jana},
   article_location = {ABINGDON},
   article_number = {1},
   doi = {https://doi.org/10.1080/09546634.2025.2460578},
   keywords = {Atopic dermatitis; dupilumab; biologics; children; efficacy; safety},
   language = {eng},
   issn = {0954-6634},
   journal = {Journal of Dermatological Treatment},
   title = {Real-world efficacy and safety of dupilumab in children with atopic dermatitis under 6 years of age: a retrospective multicentric study},
   url = {https://www.tandfonline.com/doi/full/10.1080/09546634.2025.2460578},
   volume = {36},
   year = {2025}
}

TY  - JOUR
ID  - 2514906
AU  - Rob, Filip - Pinková, Blanka - Sokolova, Kristyna - Kopuleta, Jana - Jiraskova Zakostelska, Zuzana - Cadova, Jana
PY  - 2025
TI  - Real-world efficacy and safety of dupilumab in children with atopic dermatitis under 6 years of age: a retrospective multicentric study
JF  - Journal of Dermatological Treatment
VL  - 36
IS  - 1
SP  - 1-4
EP  - 1-4
PB  - TAYLOR & FRANCIS LTD
SN  - 09546634
KW  - Atopic dermatitis
KW  - dupilumab
KW  - biologics
KW  - children
KW  - efficacy
KW  - safety
UR  - https://www.tandfonline.com/doi/full/10.1080/09546634.2025.2460578
N2  - In this multicentric real-world observational retrospective study, we evaluated the efficacy and safety of dupilumab for atopic dermatitis in children <6 years of age who underwent a minimum of 16 weeks of therapy. The analysis focused on EASI (Eczema Area and Severity Index), CDLQI (Children's Dermatology Life Quality Index), and Itch NRS (Numeric Rating Scale) changes from baseline to 4, 16, 24, 48, 72, and 96 weeks of follow-up (when available). Overall 24 children were included, with a mean age of 4.4 years. The baseline mean EASI among these patients was 26.7 (range 11.2-42.5). Since week 16 of therapy, all patients achieved and sustained at least 50% (EASI-50) atopic dermatitis improvement from baseline for the remainder of the follow-up period. At week 16, the mean EASI was 4.6 (0.8-13.1), EASI-75 reached 75% and EASI-90 38% of the patients. Within the initial 16 weeks of dupilumab treatment, 50% of patients experienced at least one adverse event, none of which were deemed severe. Conjunctivitis was among the most common adverse events (8.3%). In conclusion, dupilumab exhibited favorable tolerability, efficacy, and safety in children diagnosed with atopic dermatitis who were below the age of 6.
ER  -

ROB, Filip; Blanka PINKOVÁ; Kristyna SOKOLOVA; Jana KOPULETA; Zuzana JIRASKOVA ZAKOSTELSKA a Jana CADOVA. Real-world efficacy and safety of dupilumab in children with atopic dermatitis under 6 years of age: a retrospective multicentric study. \textit{Journal of Dermatological Treatment}. ABINGDON: TAYLOR \&{} FRANCIS LTD, 2025, roč.~36, č.~1, s.~1-4. ISSN~0954-6634. Dostupné z: https://doi.org/10.1080/09546634.2025.2460578.

Přehled o publikaci